Saturday, September 5, 2015

Cynapsus enrolls first patient in Phase 3 trial

Cynapsus enrolls first patient in Phase 3 trial

September 3, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) has enrolled the first patient in the CTH-301 clinical trial, a pivotal Phase 3 study to examine the safety and tolerability of APL-130277 for the acute treatment of OFF episodes in patients with Parkinson’s disease (PD). CTH-300, a pivotal Phase 3 efficacy study, is also ongoing with data expected from […]

BofA, Nomura start Cynapsus at buy

BofA, Nomura start Cynapsus at buy

July 14, 2015 by · Leave a Comment 

Tweet BofA Merrill Lynch and Nomura Securities initiated coverage of Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) with “buy” ratings as BofA set a target price of $33 on the stock and Nomura at $29. Cynapsus’ APL-130277 is a thin-film sublingual (under the tongue) formulation of apomorphine. The product is in Phase 3 trials for acute, on-demand or […]

Cynapsus enrols first patient in Phase 3 trial

Cynapsus enrols first patient in Phase 3 trial

June 29, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) has enrolled the first patient in the CTH-300 clinical trial, a Phase 3 study to examine the efficacy, safety and tolerability of APL-130277 for the acute treatment of “off”episodes in patients with Parkinson’s disease (PD). The CTH-300 trial is a double-blind, placebo-controlled, parallel-design study with an estimated enrollment of 126 […]

Cynapsus’ drug shown to improve Parkinson’s symptoms

Cynapsus’ drug shown to improve Parkinson’s symptoms

June 25, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) has presented data from clinical trials of APL-130277, a sublingual apomorphine thin film under development for the on-demand treatment of off episodes associated with Parkinson’s disease (PD). Data from the company’s CTH-105, CTH-104 and CTH-103 clinical studies, presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS) […]

Cynapsus prices $63-million offering

Cynapsus prices $63-million offering

June 18, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) has priced an offering of 4.5 million common shares at a price of $14 apiece for gross proceeds of approximately $63-million. The company also has granted underwriters a 30-day option to purchase up to an additional 675,000 common shares at the same price. Net proceeds will be used to fund […]

Cynapsus launches public offering, applies to dual-list on NASDAQ

Cynapsus launches public offering, applies to dual-list on NASDAQ

June 10, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) is offering to sell 4.5 million common shares in an underwritten public offering through a registration statement filed with the SEC. BofA Merrill Lynch is acting as sole book-running manager for the proposed offering, with Nomura as a lead manager, and Noble Life Science Partners as co-manager. Cynapsus also expects […]

Cynapsus files for NASDAQ listing, offering, stock rollback

Cynapsus files for NASDAQ listing, offering, stock rollback

May 15, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) has filed a registration statement with the SEC for a public offering of common stock in the U.S. and has filed an application to list on the NASDAQ Capital Market. The timing, number of shares and price per share of the proposed offering have not yet been determined. Cynapsus also […]

Cynapsus completes $21-million private placement

Cynapsus completes $21-million private placement

March 31, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) has completed a private placement of 22,039,472 common shares for gross proceeds of $20,981,579. The financing was led by funds associated with OrbiMed, Aisling Capital and Venrock, with participation from various other institutional investors, including existing shareholders, Broadfin Capital, Sphera Funds Management, Pura Vida Investments, DAFNA Capital Management and Dexcel […]

Cynapsus to start Phase 3 PD program in second quarter

Cynapsus to start Phase 3 PD program in second quarter

March 12, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) has completed an end-of-Phase 2 meeting with the FDA for its APL-130277 drug candidate for acute rescue of OFF episodes associated with Parkinson’s disease (PD). At the meeting, agreement was reached on the design, duration and size for the Phase 3 program clinical studies, as well as for primary and […]

Cynapsus to uplist to TSX on Nov. 28

Cynapsus to uplist to TSX on Nov. 28

November 25, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) will begin trading on the Toronto Stock Exchange at the opening this Friday, Nov. 28. The shares will continue to trade under the symbol CTH. Trading on the TSX Venture Exchange will end on Friday. The change does not affect trading on the OTCQX International in the U.S. “Uplisting the […]

Next Page »

Email Newsletters with Constant Contact
Google+